Table 2 American College of Rheumatology 20 response and p value comparison with placebo by treatment group and time since start of drug administration (last observation carried forward).
| Visit day | BIIL 284 | Placebo | ||
|---|---|---|---|---|
| 5 mg (n = 80) | 25 mg (n = 83) | 75 mg (n = 87) | (n = 92) | |
| Day 14 | ||||
| n (%) | 9 (11.2) | 11 (13.2) | 9 (10.3) | 9 (9.9) |
| p Value* | 0.837 | 0.479 | 0.979 | |
| Day 28 | ||||
| n (%) | 13 (16.2) | 23 (27.7) | 14 (16.1) | 14 (15.2) |
| p Value* | 0.725 | 0.042 | 0.816 | |
| Day 56 | ||||
| n (%) | 16 (20.0) | 24 (28.9) | 23 (26.4) | 16 (17.4) |
| p Value* | 0.624 | 0.070 | 0.165 | |
| Day 84† | ||||
| n (%) | 16 (20.0) | 24 (28.9) | 25 (28.7) | 17 (18.5) |
| p Value* | 0.795 | 0.097 | 0.109 | |
Results of the analysis of efficacy in the full analysis set (n = 342).
*Cochran–Mantel Haenszel test adjusted for centre effects.
†End of treatment.